Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
| Revenue (Most Recent Fiscal Year) | $196.54M |
| Net Income (Most Recent Fiscal Year) | $-140.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.66 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 11.42 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -60.67% |
| Net Margin (Trailing 12 Months) | -60.95% |
| Return on Equity (Trailing 12 Months) | -80.66% |
| Return on Assets (Trailing 12 Months) | -32.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.55 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.75 |
| Inventory Turnover (Trailing 12 Months) | 1.67 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.20 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.16 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.04 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 119.20M |
| Free Float | 108.00M |
| Market Capitalization | $1.63B |
| Average Volume (Last 20 Days) | 2.06M |
| Beta (Past 60 Months) | 1.87 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.40% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |